LIVIVO - Search results -

Search results

Result 1 - 10 of total 10

Search options

Article ; Online: Loss of humeral immunity in childhood cancer survivors not having undergone hematopoietic stem cell transplantation.

Pearson, Benjamin / Pulley, Michelle / Diniz, Marcio / Baca, Nicole / Majlessipour, Fataneh

Cancer reports (Hoboken, N.J.)

2023 Volume 6, Issue 12, Page(s) e1907

Abstract: Background: Data are limited and conflicting regarding loss of immunity in childhood cancer survivors who did not undergo hematopoietic stem cell transplantation. The purpose of this retrospective, single center study is to provide further data to help ... ...

Abstract	Background: Data are limited and conflicting regarding loss of immunity in childhood cancer survivors who did not undergo hematopoietic stem cell transplantation. The purpose of this retrospective, single center study is to provide further data to help build unifying revaccination guidelines post-chemotherapy in childhood cancer survivors not having undergone hematopoietic stem cell transplantation. Methods: This retrospective study included 28 childhood cancer survivors, 14 males and 14 females, whose treatment consisted of at least 3 months of chemotherapy and with confirmation of completing their primary vaccination series prior to therapy. The rate of vaccine titer seropositivity for cancer survivors was compared with the expected general population, based on long-term studies of anti-body persistence. Results: Decreased seropositivity for measles, mumps, rubella, varicella, tetanus, and hepatitis B was found in patients across all categories of malignancy compared with the general population. However, tetanus was not statistically significant. Results were more pronounced for those with hematological malignancies. Conclusions: This study indicates that pediatric cancer survivors, especially those with hematological malignancies, may have greater loss of protective antibodies from primary vaccinations. Further studies are needed to provide guidelines for revaccination of both hematologic malignancies and solid tumor childhood cancer survivors who did not undergo hematopoietic stem cell transplantation.
MeSH term(s)	Male ; Female ; Humans ; Child ; Retrospective Studies ; Cancer Survivors ; Neoplasms/drug therapy ; Vaccination ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hematologic Neoplasms
Language	English
Publishing date	2023-10-22
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2573-8348
ISSN (online)	2573-8348
DOI	10.1002/cnr2.1907
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Ganglioneuroblastoma in a Child With Neurofibromatosis Type 1: A Case Report and Literature Review.

Okonta, Vivian N / Majlessipour, Fataneh / Baca, Nicole M

Journal of pediatric hematology/oncology

2022 Volume 45, Issue 1, Page(s) e131–e134

Abstract: Neurofibromatosis type 1 (NF1) is a genetic condition commonly associated with a predisposition to tumor development. Affected individuals have an increased risk of benign and malignant tumors of the central and peripheral nervous system. Though ... ...

Abstract	Neurofibromatosis type 1 (NF1) is a genetic condition commonly associated with a predisposition to tumor development. Affected individuals have an increased risk of benign and malignant tumors of the central and peripheral nervous system. Though pediatric patients with NF1 have an increased risk of tumors such as optic gliomas and neurofibromas during childhood, neuroblastic tumors are less often observed in this population. We report a rare case of a 5-year-old female with ganglioneuroblastoma intermixed and known history of NF1 and review the existing literature on the occurrence of ganglioneuroblastoma in pediatric patients with NF1.
MeSH term(s)	Female ; Humans ; Child ; Child, Preschool ; Neurofibromatosis 1/genetics ; Ganglioneuroblastoma ; Neurofibroma/complications ; Neurofibroma/genetics ; Optic Nerve Glioma ; Genotype
Language	English
Publishing date	2022-04-06
Publishing country	United States
Document type	Review ; Case Reports ; Journal Article
ZDB-ID	1231152-2
ISSN	1536-3678 ; 1077-4114 ; 0192-8562
ISSN (online)	1536-3678
ISSN	1077-4114 ; 0192-8562
DOI	10.1097/MPH.0000000000002461
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1537: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Ewing's Sarcoma in a Patient with Crohn's Disease Treated with Ustekinumab: A Case Report.

Rao, Rameshwar R / Majlessipour, Fataneh / Ziring, David A / Baca, Nicole M

Journal of adolescent and young adult oncology

2020 Volume 10, Issue 5, Page(s) 614–617

Abstract: Biologic therapies have revolutionized the treatment of immune-mediated diseases. They are generally well tolerated; however, there are reports of malignancies associated with the use of these drugs. This case is of an adolescent with refractory Crohn's ... ...

Abstract	Biologic therapies have revolutionized the treatment of immune-mediated diseases. They are generally well tolerated; however, there are reports of malignancies associated with the use of these drugs. This case is of an adolescent with refractory Crohn's disease treated with ustekinumab, who subsequently developed Ewing's sarcoma. Patients treated with ustekinumab have reportedly developed B cell lymphoma, epithelioid sarcoma, as well as cancer of the lung, esophagus, ovary, testis, kidney, and thyroid. However, this is the first documented case of a patient treated with ustekinumab to develop Ewing sarcoma.
MeSH term(s)	Adolescent ; Crohn Disease/drug therapy ; Female ; Humans ; Male ; Sarcoma ; Sarcoma, Ewing/drug therapy ; Ustekinumab/therapeutic use
Chemical Substances	Ustekinumab (FU77B4U5Z0)
Language	English
Publishing date	2020-09-22
Publishing country	United States
Document type	Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2607978-1
ISSN	2156-535X ; 2156-5333
ISSN (online)	2156-535X
ISSN	2156-5333
DOI	10.1089/jayao.2020.0077
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Transient myeloproliferative disorder as the presenting feature for mosaic trisomy 21.

Baca, Nicole / Sanchez-Lara, Pedro A / Schreck, Rhona / Eno, Celeste C / Majlessipour, Fataneh

Cold Spring Harbor molecular case studies

2021 Volume 7, Issue 6

Abstract: Trisomy 21 is a common congenital disorder with well-documented clinical manifestations, including an increased risk for the transient myeloproliferative disorder as a neonate and leukemia in childhood and adolescence. Transient myeloproliferative ... ...

Abstract	Trisomy 21 is a common congenital disorder with well-documented clinical manifestations, including an increased risk for the transient myeloproliferative disorder as a neonate and leukemia in childhood and adolescence. Transient myeloproliferative disorder is only known to occur in hematopoietic cells with trisomy 21. Children with mosaic trisomy 21 also have a risk for hematological malignancies. We present a nondysmorphic neonate, with a negative noninvasive prenatal screening of maternal blood for trisomy 21, who came to medical attention because of ruddy skin. He was found to have mild polycythemia, thrombocytopenia, and developed peripheral blasts. His clinical presentation was consistent with transient myeloproliferative disorder, which is only seen with trisomy 21. Cytogenetic studies of peripheral blood are positive for mosaic trisomy 21.
MeSH term(s)	Chromosomes, Human, Pair 21 ; Down Syndrome ; Female ; Humans ; Male ; Mosaicism ; Myeloproliferative Disorders ; Pregnancy ; Trisomy ; Uniparental Disomy
Language	English
Publishing date	2021-12-09
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	2835759-0
ISSN	2373-2873 ; 2373-2873
ISSN (online)	2373-2873
ISSN	2373-2873
DOI	10.1101/mcs.a006126
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: RELA Fusion-Positive Ependymoma in a Child with Down Syndrome: A Case Report.

Chan, Julie L / Kashanian, Alon / Bannykh, Serguei I / Majlessipour, Fataneh / Breunig, Joshua J / Danielpour, Moise

Pediatric neurosurgery

2021 Volume 56, Issue 2, Page(s) 146–151

Abstract: Introduction: Down syndrome (DS) is the most common multiple malformation syndrome in humans and is associated with an increased risk of childhood malignancy, particularly leukemia. Incidence of brain tumors in patients with DS is limited to sporadic ... ...

Abstract	Introduction: Down syndrome (DS) is the most common multiple malformation syndrome in humans and is associated with an increased risk of childhood malignancy, particularly leukemia. Incidence of brain tumors in patients with DS is limited to sporadic cases. We report the first case of a RELA fusion-positive ependymoma in a 3-year-old boy with DS. Case presentation: Imaging prompted by new left-sided hemiparesis demonstrated an 8-cm hemorrhagic right temporal-parietal mass. Subsequent image-complete resection confirmed a RELA fusion-positive anaplastic ependymoma with 90% OLIG2 staining. Postoperatively, the patient, unfortunately, experienced fatal recurrence and drop metastases with leptomeningeal involvement. Conclusion: To our knowledge, this is the first reported case of a confirmed RELA fusion-positive ependymoma in a child with DS. We discuss this finding in the context of intracranial tumors in children with DS, as well as the finding of 90% positive OLIG2 expression and its potential as a prognostic marker.
MeSH term(s)	Brain Neoplasms/diagnostic imaging ; Brain Neoplasms/genetics ; Brain Neoplasms/surgery ; Child ; Child, Preschool ; Down Syndrome/complications ; Ependymoma/complications ; Ependymoma/diagnostic imaging ; Ependymoma/genetics ; Glioma ; Humans ; Male ; Supratentorial Neoplasms ; Transcription Factor RelA
Chemical Substances	RELA protein, human ; Transcription Factor RelA
Language	English
Publishing date	2021-03-09
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	1091757-3
ISSN	1423-0305 ; 1016-2291
ISSN (online)	1423-0305
ISSN	1016-2291
DOI	10.1159/000511673
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1133: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Southern California Pediatric and Adolescent Cancer Survivorship (SC-PACS): Establishing a Multi-Institutional Childhood, Adolescent, and Young Adult Cancer Survivorship Consortium in Southern California.

Lin, Carol / Baca, Nicole / Yun, Christine / Armenian, Saro / Freyer, David R / Majlessipour, Fataneh / Mueller, Lisa / Kuo, Dennis J / Casillas, Jacqueline / Zabokrtsky, Keri / Ehwerhemuepha, Louis / Torno, Lilibeth

Cureus

2022 Volume 14, Issue 2, Page(s) e21981

Abstract: Introduction Given their risk for late effects and early mortality, childhood/adolescent cancer survivors (CACSs) should receive longitudinal monitoring and care. The Southern California Pediatric and Adolescent Cancer Survivorship (SC-PACS) consortium ... ...

Abstract	Introduction Given their risk for late effects and early mortality, childhood/adolescent cancer survivors (CACSs) should receive longitudinal monitoring and care. The Southern California Pediatric and Adolescent Cancer Survivorship (SC-PACS) consortium was established in February 2017 to combine resources and expertise across seven participating survivorship programs. Its over-arching objective is to address the unique needs of its demographically diverse CACS population through collaborative survivorship research and care initiatives. The first SC-PACS study was an assessment of survivorship needs and evaluation of current services as reported by CACSs and their parents/primary care givers (PPCGs) receiving survivorship care at consortium sites. Methods As an initial investigation, a cross-sectional survey for CACSs and their parents/primary care givers was conducted. The goal was to enroll 10 CACSs and 10 PPCGs from each of the seven institutions (total of 140 participants). The eligibility criteria for CACSs were age ≥13 years at the time of enrollment, >2 years from the end of treatment, sufficient cognitive function to complete the survey, and English or Spanish language proficiency. For CACSs <13 years old, their PPCGs completed the survey. This was a convenience sample using frequencies and proportions to describe participant characteristics and survey responses, which were entered into a Research Electronic Data Capture (REDCap) database. Results Across the consortium, of the recruitment target of 140 participants (CACSs, n=70; PPCGs, n=70), 127 (90.7%) participants were enrolled. Of the 127 participants enrolled, 65 (51.2%) were CACSs and 62 (48.8%) were PPCGs. The majority of participants were female (51.2%), were Hispanic (62.2%), spoke English as the primary language at home (57.5%), and were diagnosed between one to four years of age (45.7%). Information considered most important by both CACSs and PPCGs was related to cancer diagnosis (90.8%) and future risks as a result of cancer treatment received (98.0%). Overall, 78% of CACSs and PPCGs found the survivorship information (treatment summary) useful, and 83% felt that they received the right amount of information about their cancer. Conclusion Our aim was to obtain baseline data that would characterize our CACS population, inform consortium priorities, and establish a collaborative research platform. The ultimate goal of the consortium is to develop a comprehensive survivorship care approach that addresses the most important needs of cancer survivors in our catchment area and promotes best practice interventions. Future plans are to expand the needs assessment survey to obtain a wider representation of the survivor population at SC-PACS institutions, helping create strategies to improve cancer-specific education, delivery of treatment summary, and access to community resources for this demographically and socioeconomically diverse population.
Language	English
Publishing date	2022-02-07
Publishing country	United States
Document type	Journal Article
ZDB-ID	2747273-5
ISSN	2168-8184
ISSN	2168-8184
DOI	10.7759/cureus.21981
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease.

Madany, Emaan / Lee, June / Halprin, Chelsea / Seo, Jina / Baca, Nicole / Majlessipour, Fataneh / Hendrickson, Jeanne E / Pepkowitz, Samuel H / Hayes, Chelsea / Klapper, Ellen / Gibb, David R

EJHaem

2021 Volume 2, Issue 4, Page(s) 700–710

Abstract: Patients with sickle cell disease (SCD) have a high prevalence of RBC alloimmunization. However, underlying mechanisms are poorly understood. Given that proinflammatory type 1 interferons ( ... ...

Abstract	Patients with sickle cell disease (SCD) have a high prevalence of RBC alloimmunization. However, underlying mechanisms are poorly understood. Given that proinflammatory type 1 interferons (IFN
Language	English
Publishing date	2021-07-27
Publishing country	United States
Document type	Journal Article
ISSN	2688-6146
ISSN (online)	2688-6146
DOI	10.1002/jha2.270
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The effects of everolimus on tuberous sclerosis-associated lesions can be dramatic but may be impermanent.

Miller, Joseph M / Wachsman, Ashley / Haker, Katherine / Majlessipour, Fataneh / Danielpour, Moise / Puliyanda, Dechu

Pediatric nephrology (Berlin, Germany)

2014 Volume 30, Issue 1, Page(s) 173–177

Abstract: Background: Tuberous sclerosis complex (TSC) predisposes to the development of benign lesions within multiple organ systems, including the brain, kidneys, heart, lungs, and skin. Disease mortality is due to space-occupying subependymal giant cell ... ...

Abstract	Background: Tuberous sclerosis complex (TSC) predisposes to the development of benign lesions within multiple organ systems, including the brain, kidneys, heart, lungs, and skin. Disease mortality is due to space-occupying subependymal giant cell astrocytomas and hemorrhage-prone renal angiomyolipomas. The recent use of mTORC1 inhibitors, such as everolimus, has allowed for direct targeting of TSC-associated mass lesions without apparent effect on surrounding tissues. Because of the mechanism of these drugs, there is reason to believe that these effects are not durable and that there may be need for continued long-term maintenance therapy. Case-diagnosis/treatment: We present a case of TSC-associated mass lesions that were ill-suited for definitive surgical therapy. The patient was started on everolimus, however due to a complex social situation treatment was discontinued and ultimately resumed many months later. Radiologic studies acquired before and after each period of therapeutic onset/cessation reveal the dramatic but impermanent effects of mTORC1 inhibition. Conclusions: While everolimus provides a non-invasive way to treat TSC-associated lesions, patients may require lifelong therapy. When termination of therapy is considered, the patient should be made aware of the expectation of potentially dramatic increases in lesion size. If consideration is to be given to definitive surgical therapy, it should be pursued while the patient is still on the medication, or at least soon after treatment is halted.
MeSH term(s)	Adolescent ; Everolimus ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Sirolimus/analogs & derivatives ; Sirolimus/therapeutic use ; Tuberous Sclerosis/drug therapy ; Tuberous Sclerosis/pathology ; Tuberous Sclerosis/physiopathology
Chemical Substances	Immunosuppressive Agents ; Everolimus (9HW64Q8G6G) ; Sirolimus (W36ZG6FT64)
Language	English
Publishing date	2014-09-07
Publishing country	Germany
Document type	Case Reports ; Journal Article
ZDB-ID	631932-4
ISSN	1432-198X ; 0931-041X
ISSN (online)	1432-198X
ISSN	0931-041X
DOI	10.1007/s00467-014-2949-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2196: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Primary EBV infection resulting in lymphoproliferative disease in a teenager with Crohn disease.

Gidrewicz, Dominica / Lehman, Deborah / Rabizadeh, Shervin / Majlessipour, Fataneh / Dubinsky, Marla

Journal of pediatric gastroenterology and nutrition

2010 Volume 52, Issue 1, Page(s) 103–105

MeSH term(s)	Adolescent ; Anti-Inflammatory Agents/adverse effects ; Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Azathioprine/adverse effects ; Azathioprine/therapeutic use ; Crohn Disease/complications ; Crohn Disease/drug therapy ; Crohn Disease/immunology ; Epstein-Barr Virus Infections/complications ; Epstein-Barr Virus Infections/diagnosis ; Epstein-Barr Virus Infections/drug therapy ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Infliximab ; Lymphoproliferative Disorders/complications ; Methylprednisolone/adverse effects ; Methylprednisolone/therapeutic use
Chemical Substances	Anti-Inflammatory Agents ; Antibodies, Monoclonal ; Immunosuppressive Agents ; Infliximab (B72HH48FLU) ; Azathioprine (MRK240IY2L) ; Methylprednisolone (X4W7ZR7023)
Language	English
Publishing date	2010-10-01
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	603201-1
ISSN	1536-4801 ; 0277-2116
ISSN (online)	1536-4801
ISSN	0277-2116
DOI	10.1097/MPG.0b013e3181e80410
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1728: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.

Avramis, Vassilios I / Sencer, Susan / Periclou, Antonia P / Sather, Harland / Bostrom, Bruce C / Cohen, Lewis J / Ettinger, Alice G / Ettinger, Lawrence J / Franklin, Janet / Gaynon, Paul S / Hilden, Joanne M / Lange, Beverly / Majlessipour, Fataneh / Mathew, Pracad / Needle, Michael / Neglia, Joseph / Reaman, Gregory / Holcenberg, John S / Stork, Linda

Blood

2002 Volume 99, Issue 6, Page(s) 1986–1994

Abstract: For this study, 118 children with standard-risk acute lymphoblastic leukemia (ALL) were given randomized assignments to receive native or pegylated Escherichia coli asparaginase as part of induction and 2 delayed intensification phases. Patients treated ... ...

Abstract	For this study, 118 children with standard-risk acute lymphoblastic leukemia (ALL) were given randomized assignments to receive native or pegylated Escherichia coli asparaginase as part of induction and 2 delayed intensification phases. Patients treated with pegaspargase had more rapid clearance of lymphoblasts from day 7 and day 14 bone marrow aspirates and more prolonged asparaginase activity than those treated with native asparaginase. In the first delayed intensification phase, 26% of native asparaginase patients had high-titer antibodies, whereas 2% of pegaspargase patients had those levels. High-titer antibodies were associated with low asparaginase activity in the native arm, but not in the pegaspargase arm. Adverse events, infections, and hospitalization were similar between arms. Event-free survival at 3 years was 82%. A population pharmacodynamic model using the nonlinear mixed effects model (NONMEM) program was developed that closely fit the measured enzyme activity and asparagine concentrations. Half-lives of asparaginase were 5.5 days and 26 hours for pegaspargase and native asparaginase, respectively. There was correlation between asparaginase enzymatic activity and depletion of asparagine or glutamine in serum. In cerebrospinal fluid asparagine, depletion was similar with both enzyme preparations. Intensive pegaspargase for newly diagnosed ALL should be tested further in a larger population.
MeSH term(s)	Amino Acids/blood ; Antibodies/blood ; Asparaginase/administration & dosage ; Asparaginase/immunology ; Asparaginase/pharmacokinetics ; Biotransformation ; Bone Marrow/drug effects ; Bone Marrow/pathology ; Child ; Child, Preschool ; Escherichia coli/enzymology ; Female ; Humans ; Infant ; Male ; Polyethylene Glycols/administration & dosage ; Polyethylene Glycols/pharmacokinetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Safety ; Therapeutic Equivalency ; Treatment Outcome
Chemical Substances	Amino Acids ; Antibodies ; Polyethylene Glycols (3WJQ0SDW1A) ; pegaspargase (7D96IR0PPM) ; Asparaginase (EC 3.5.1.1)
Language	English
Publishing date	2002-03-15
Publishing country	United States
Document type	Clinical Trial ; Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.v99.6.1986
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito